Almost 2bn to Be Affected by Metabolic Liver Disease by 2050, Study Suggests

Why It Matters

MASLD’s explosive growth threatens to strain health systems and increase future liver‑related complications, making early detection and lifestyle interventions a global priority.

Key Takeaways

• MASLD cases projected to reach 1.8 billion by 2050
• Prevalence rose 143% from 1990 to 2023
• High blood sugar is top risk factor worldwide
• UK prevalence rose 33% from 1990‑2023, highest in Western Europe
• Early‑stage disease drives case surge while mortality remains stable

Pulse Analysis

The Lancet‑backed Global Burden of Disease analysis underscores that metabolic liver disease is no longer a niche concern but a looming public‑health crisis. With 1.3 billion people already living with MASLD—a 143% jump since 1990—the condition’s trajectory points to 1.8 billion affected by mid‑century. This surge reflects not only population growth but also a worldwide shift toward sedentary lifestyles, higher caloric intake, and rising prevalence of type 2 diabetes. The disease’s silent nature, often discovered incidentally, means many remain undiagnosed until advanced stages, amplifying future treatment costs.

Key drivers of the epidemic are clear: elevated blood‑sugar levels top the risk hierarchy, followed closely by high body‑mass index and smoking. These metabolic stressors are especially pronounced in regions such as North Africa and the Middle East, where rapid urbanization has outpaced preventive health measures. Notably, the study highlights a demographic shift—while older adults still hold the highest prevalence rates, the absolute number of cases is climbing fastest among individuals in their mid‑30s to late‑50s. This younger burden signals that lifestyle‑related risk factors are taking hold earlier, compressing the window for effective intervention.

For policymakers and health‑care providers, the data demand a two‑pronged response. First, public‑health campaigns must prioritize education on diet, physical activity, and glucose control to curb the upstream drivers of MASLD. Second, health systems should expand screening protocols, especially for at‑risk groups, to catch the disease in its reversible early stages. Although advances in treatment have stabilized years‑lost metrics, the sheer volume of new cases threatens to overwhelm liver‑specialty services and increase downstream complications like cirrhosis and cancer. Proactive investment now could avert a costly wave of advanced liver disease in the decades ahead.